167 related articles for article (PubMed ID: 28449009)
21. Cluster analysis of dynamic contrast enhanced MRI reveals tumor subregions related to locoregional relapse for cervical cancer patients.
Torheim T; Groendahl AR; Andersen EK; Lyng H; Malinen E; Kvaal K; Futsaether CM
Acta Oncol; 2016 Nov; 55(11):1294-1298. PubMed ID: 27564398
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers.
Andersen EK; Kristensen GB; Lyng H; Malinen E
Acta Oncol; 2011 Aug; 50(6):859-65. PubMed ID: 21767185
[TBL] [Abstract][Full Text] [Related]
23. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594
[TBL] [Abstract][Full Text] [Related]
24. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer.
Zahra MA; Tan LT; Priest AN; Graves MJ; Arends M; Crawford RA; Brenton JD; Lomas DJ; Sala E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):766-73. PubMed ID: 19019563
[TBL] [Abstract][Full Text] [Related]
25. Added-value of dynamic contrast-enhanced MRI on prediction of tumor recurrence in locally advanced cervical cancer treated with chemoradiotherapy.
Zhang Q; Guo J; Ouyang H; Chen S; Zhao X; Yu X
Eur Radiol; 2022 Apr; 32(4):2529-2539. PubMed ID: 34647177
[TBL] [Abstract][Full Text] [Related]
26. Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy.
Vojtíšek R; Baxa J; Kovářová P; Almortaza A; Hošek P; Sukovská E; Tupý R; Ferda J; Fínek J
Strahlenther Onkol; 2021 Jun; 197(6):494-504. PubMed ID: 33492444
[TBL] [Abstract][Full Text] [Related]
27. [Application on the quantitative perfusion parameters of dynamic contrast-enhanced MRI in the pathological subtype of uterine leiomyoma].
Zheng J; Zhao ZH; Yang JF; Zhao L; Yang LM; Hu HJ
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(15):1155-1159. PubMed ID: 28427122
[No Abstract] [Full Text] [Related]
28. Combined dynamic DCE-MRI and diffusion-weighted imaging to evaluate the effect of neoadjuvant chemotherapy in cervical cancer.
Feng Y; Liu H; Ding Y; Zhang Y; Liao C; Jin Y; Ai C
Tumori; 2020 Apr; 106(2):155-164. PubMed ID: 31736439
[TBL] [Abstract][Full Text] [Related]
29. Measurement of rat brain tumor kinetics using an intravascular MR contrast agent and DCE-MRI nested model selection.
Chwang WB; Jain R; Bagher-Ebadian H; Nejad-Davarani SP; Iskander AS; VanSlooten A; Schultz L; Arbab AS; Ewing JR
J Magn Reson Imaging; 2014 Nov; 40(5):1223-9. PubMed ID: 24421265
[TBL] [Abstract][Full Text] [Related]
30. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
Law M; Young R; Babb J; Rad M; Sasaki T; Zagzag D; Johnson G
AJNR Am J Neuroradiol; 2006 Oct; 27(9):1975-82. PubMed ID: 17032878
[TBL] [Abstract][Full Text] [Related]
31. Intravoxel Incoherent Motion Combined With Dynamic Contrast-Enhanced Perfusion MRI of Early Cervical Carcinoma: Correlations Between Multimodal Parameters and HIF-1α Expression.
Li X; Wu S; Li D; Yu T; Zhu H; Song Y; Meng L; Fan H; Xie L
J Magn Reson Imaging; 2019 Sep; 50(3):918-929. PubMed ID: 30648775
[TBL] [Abstract][Full Text] [Related]
32. Dynamic contrast-enhanced magnetic resonance imaging in cervical cancer: correlation between quantitative parameters and molecular markers hypoxia-inducible factors-1-alpha, vascular endothelial growth factor, and Ki-67.
Liu B; Gao H; Zhou F; Zhao W; Yang Y
Clin Radiol; 2024 Jun; 79(6):e826-e833. PubMed ID: 38582634
[TBL] [Abstract][Full Text] [Related]
33. Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer.
Dogan BE; Yuan Q; Bassett R; Guvenc I; Jackson EF; Cristofanilli M; Whitman GJ
Curr Probl Diagn Radiol; 2019; 48(3):235-240. PubMed ID: 29685400
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of Gd-DTPA and gadomelitol as contrast agents in DCE-MRI of cervical carcinoma interstitial fluid pressure.
Hompland T; Ellingsen C; Rofstad EK
BMC Cancer; 2012 Nov; 12():544. PubMed ID: 23173554
[TBL] [Abstract][Full Text] [Related]
35. Assessment of liver fibrosis using pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging.
Li Z; Sun J; Chen L; Huang N; Hu P; Hu X; Han G; Zhou Y; Bai W; Niu T; Yang X
J Magn Reson Imaging; 2016 Jul; 44(1):98-104. PubMed ID: 26707910
[TBL] [Abstract][Full Text] [Related]
36. Assessment of early response to concurrent chemoradiotherapy in cervical cancer: value of diffusion-weighted and dynamic contrast-enhanced MR imaging.
Park JJ; Kim CK; Park SY; Simonetti AW; Kim E; Park BK; Huh SJ
Magn Reson Imaging; 2014 Oct; 32(8):993-1000. PubMed ID: 24970025
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours?
Little RA; Barjat H; Hare JI; Jenner M; Watson Y; Cheung S; Holliday K; Zhang W; O'Connor JPB; Barry ST; Puri S; Parker GJM; Waterton JC
Magn Reson Imaging; 2018 Feb; 46():98-105. PubMed ID: 29154898
[TBL] [Abstract][Full Text] [Related]
38. Combined dynamic contrast enhanced MRI parameter with clinical factors predict the survival of concurrent chemo-radiotherapy in patients with 2018 FIGO IIICr stage cervical cancer.
Qin F; Pang H; Ma J; Zhao M; Jiang X; Tong R; Yu T; Luo Y; Dong Y
Eur J Radiol; 2021 Aug; 141():109787. PubMed ID: 34051683
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
Lim A; Sia S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
[TBL] [Abstract][Full Text] [Related]
40. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
